EXPERIENCES WITH THE APPLICATION OF THE T OPICAL GLUCOCORTICOID POWDER FLUOCORTIN BUTYL FOR PATIENTS WITH ALLERGIC RHINITIS

Efficacy and safety data of the topical glucocorticosteroid fluocortin butyl (FCB) (Lenen) were recorded for 4,440 patients with seasonal (6 2.5%), perennial (25.7%) and other allergic rhinitis (11.7%). Adverse events were documented for 2.2% of the patients, Apart from mild irrit ations at the nose only known side effects of FCB were observed. Accor ding to the doctor's assessment 93.8% of the patients with seasonal rh initis became free of symptoms (42.5%) or improved (51.3%), and 87.8% of the patients with perennial rhinitis (26.8% free of symptoms, 61% i mproved). In accordance, the therapeutic effect was more frequently as sessed as good by patients with seasonal rhinitis (83.8%) than by pati ents with perennial rhinitis (75.6%). More patients who had exclusivel y applied FCB became free of symptoms (42.5%) than patients with a con comitant antiallergic medication (23.3%). The assessment of the therap eutic effect was independent of the applied dose of FCB (2, 3 or 4 tim es/day). This study for broad application has shown that FCB is effici ent and well tolerated.